Advanced manufacturing in regenerative medicine is the new focus of SAS |  WRAL Tech Wire

Advanced manufacturing in regenerative medicine is the new focus of SAS | WRAL Tech Wire

RESEARCH TRIANGLE PARK – Winston-Salem-based nonprofit Regenerative Medicine Development Organization (ReMDO) and Cary-based analytics company SAS are joining forces to improve advanced manufacturing for regenerative medicine applications.

SAS will bring its expertise in Internet of Things (IoT) analytics and smart manufacturing to ReMDO’s RegeneratOR testbed, a ‘manufacturing-in-a-box’ facility that provides companies with state-of-the-art biomanufacturing equipment, industry expertise, talent and training programs to support the prototyping of new prototypes and the development of commercial products.

SAS also brings decades of life science experience to the alliance, providing technologies to help companies improve the development, manufacturing and commercialization of medical therapies.

RegeneratOR Test Bed Core Tech Katie Benson oversees the equipment.
Photo ReMDO

This collaboration aims to help regenerative medicine companies improve product yield while reducing variability, contamination and cost.

“Regenerative medicine has been called the next evolution in medical treatments, and SAS is excited to play a part in this innovative and important endeavor,” said Udo Sglavo, Vice President of Advanced Analytics R&D at SAS. “SAS’ IoT Division and Advanced Analytics Center of Excellence will apply our related industry expertise, proven software solutions and data analytics techniques to the RegeneratOR testbed to advance manufacturing potential and help achieve best results.

The testbed is provided by ReMDO, a nonprofit foundation dedicated to advancing regenerative medicine nationwide, and the Wake Forest Institute for Regenerative Medicine (WFIRM), the largest institute for regenerative medicine in the world.

Joshua Hunsberger, Ph.D., chief technology officer of ReMDO, said SAS technology would be a game-changer for startups.

“Smart manufacturing capabilities will be available to any company in our regenerative medicine hub,” he said, referring to the Triad region’s regenerative medicine ecosystem. “These services will help companies optimize and predict the best manufacturing processes that could save time and money.”

Anthony Atala, MD, Director of WFIRM, said, “We believe that the test bed, through its collaboration with SAS, has a lot to offer to help these companies succeed, and, at the same time, we can advance regeneration field of medicine nationwide.

The testbed is one of three focus areas operating under ReMDO’s RegeneratOR initiative, which promotes the scaling up and automation of biomanufacturing to make technologies more affordable and accelerate translation into practice. clinical.

The other two focus areas are the Innovation Accelerator, which supports innovation from research to commercialization for regenerative medicine companies of all sizes, and the Workforce Development Program, which connects colleges, university programs, and technical schools with biomanufacturing personnel, engineers, and research leaders to train biomanufacturing technicians and researchers.

More than 30 companies and organizations are involved in RegeneratOR.

“It’s exciting to see North Carolina’s world-renowned expertise from academia and industry working together to help companies advance and attract new opportunities within this growing regenerative medicine center.” said Nancy Johnston, executive director of the Piedmont Triad Office at the North Carolina Biotechnology Center. The Center is a partner of SAS and WFIRM and its associated offshoots, and Atala is a board member of NCBiotech.

ReMDO, WFIRM and their various resources are based in the Winston-Salem Innovation District, a downtown neighborhood focused on research, business and education in biomedical sciences, information technology, digital media, clinical services and advanced materials.

Regenerative medicine is a relatively new and rapidly growing field of medicine that aims to augment, repair, replace, or regenerate human or animal organs, tissues, cells, genes, and metabolic processes damaged by disease, injury, or aging.

The global regenerative medicine market reached $9.8 billion in 2021 and is expected to reach $37.1 billion by 2030, growing at a compound annual growth rate of 15.9%, according to recent analysis by Emergen Research, a Canadian market research and consultancy firm based in Surrey. , British Columbia.

(C) NC Biotechnology Center


#Advanced #manufacturing #regenerative #medicine #focus #SAS #WRAL #Tech #Wire

Leave a Comment

Your email address will not be published. Required fields are marked *